Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392026 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability of Metronidazole Gel 1.3%
A Phase 4 study, sponsored by Insud Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT02392026: Completed Phase 4 study, sponsored by Insud Pharma.
NCT02392026 is a Phase 4 study that has completed, run by Insud Pharma. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02392026, a Phase 4 study, has completed, sponsored by Insud Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.
Primary Outcome
No serious AEs reported during the completed study
Interventions
- DRUG Metronidazole Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-08-12 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 4 |
What the finished NCT02392026 record still lists
NCT02392026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Metronidazole Gel is the first listed.
NCT02392026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02392026 about?
NCT02392026 is a clinical study titled "Safety and Tolerability of Metronidazole Gel 1.3%". Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.
What is the current status of trial NCT02392026?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2015-08-12. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT02392026?
The interventions under investigation include: Metronidazole Gel (DRUG).
Who is sponsoring clinical trial NCT02392026?
This trial is sponsored by Insud Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02392026's enrollment target sits among peer trials
60 1125th of 2000 higher than 799 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI